Patents by Inventor Henry F. McFarland

Henry F. McFarland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
    Patent number: 8293800
    Abstract: The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.
    Type: Grant
    Filed: April 28, 2010
    Date of Patent: October 23, 2012
    Assignees: Santhera Pharmaceuticals (Schweiz) AG, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas Meier, Bibiana Bielekova, Henry F. McFarland
  • QUINONE DERIVATIVE 2,3-DIMETHOXY-5-METHYL-6-(10-HYDROXYDECYL)-1,4-BENZOQUINONE FOR THE TREATMENT OF PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS
    Publication number: 20100280130
    Abstract: The present invention relates to approaches, methods, pharmaceuticals and uses directed to the curative treating or preventing of Primary Progressive Multiple Sclerosis (PP-MS), by using 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (Idebenone) as the active agent.
    Type: Application
    Filed: April 28, 2010
    Publication date: November 4, 2010
    Applicants: SANTHERA PHARMACEUTICALS (SCHWEIZ) AG, The U.S.A., as represented by the Secretary, Department of Health and Human Services
    Inventors: Thomas Meier, Bibiana Bielekova, Henry F. McFarland
  • Peptide mixtures with immunomodulatory activity
    Publication number: 20090214580
    Abstract: The present invention is related to complex peptide mixtures with immunomodulatory effects and methods for their use. The invention is further directed toward treatments of diseases through the modulation of the immune system with complex peptide mixtures. The invention is also directed to methods for improving the characteristics of complex peptide mixtures.
    Type: Application
    Filed: February 2, 2005
    Publication date: August 27, 2009
    Inventors: Richard A. Houghten, Clemencia Pinilla, Roland Martin, Claus-Steffen Sturzebecher, Jacquline Shukaiak-Quant, Henry F. McFarland
  • Modified myelin basic protein molecules
    Patent number: 7041503
    Abstract: Compositions and methods are provided for the clinical assessment, diagnosis, and treatment of multiple sclerosis. The compositions of the invention are molecules related to the 21.5 kDa fetal isoform of human myelin basic protein, and include nucleic acids and polypeptides. The nucleic acid molecules of the invention are useful in the efficient production of modified and unmodified 21.5 kDa myelin basic protein polypeptides, such polypeptides being useful for assaying T cells for responsiveness to myelin basic protein epitopes. The polypeptides of the invention are also useful as therapeutic agents that act by inducing T cell responses, including apoptosis, as a means of treating multiple sclerosis.
    Type: Grant
    Filed: May 2, 1995
    Date of Patent: May 9, 2006
    Assignees: The United States of America as represented by the Department of Health and Human Services, Alexion Pharmaceuticals, Inc.
    Inventors: Steven H. Nye, Michael J. Lenardo, Henry F. McFarland, Louis A. Matis, Eileen Elliott Mueller, John P. Mueller, Clara M. Pelfrey, Stephen P. Squinto, James A. Wilkins